S&P 500
7,417.60
+0.23%
Dow Jones
52,070.90
+0.42%
Nasdaq 100
29,595.00
+0.22%
Russell 2000
2,997.06
+0.50%
FTSE 100
10,476.30
+0.14%
Nikkei 225
70,174.70
+1.23%
Live: Will Micron Crush Q3 Earnings Tonight After Tuesday’s 13% Selloff?

Health and Healthcare

Sanofi, Regeneron Get Positive News from Drug Trials (SNY, REGN)

Photo of Paul Ausick
By Paul Ausick Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
An anti-cholesterol drug being co-developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has shown positive results in two Phase II trials the companies reported this morning. The investigational drug, SAR236553/REGN727, reduced levels of LDL-C, or “bad,” cholesterol in 40%-72% of patients who were taking stable doses of statin drugs.

The drug could be important in helping patients reduce cholesterol levels further when they reach the limitations of what a statin drug can do, according to a press release.

The news has boosted Regeneron shares to a new 52-week high of $121.14, up more than 1%. Sanofy’s ADS are also up about 1% at $38.72.

DISCLOSURE:
INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Jon C. Ogg |

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more…

Chris Lange |

Have Analysts Fully Priced in Praluent to Regeneron?

ThinkstockRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA)…

Chris Lange |

How Amgen Can Disrupt the Market for Cholesterol Drugs

Amgen has the potential to disrupt the market for cholesterol drugs with the newest addition to its drug portfolio.

Will a PCSK9 Inhibitor Price Cut Help Drive Lowering LDL-Cholesterol Drug Use?
Jon C. Ogg |

Will a PCSK9 Inhibitor Price Cut Help Drive Lowering LDL-Cholesterol Drug Use?

Regeneron Pharmaceuticals and Sanofi are committing to lowering the price of the anti-cholesterol drug Praluent.

As Trump Cuts Drug Prices, These Are the 50 Most Prescribed Drugs In The US
Kristin Hitchcock |

As Trump Cuts Drug Prices, These Are the 50 Most Prescribed Drugs In The US

“The president is dead serious about lowering drug prices,” said one Whitehouse representative, commenting on President Trump’s commitment to slash…

3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential
Lee Jackson |

3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential

The analysts at Stifel have noted three biotech companies that not only have data that could prove to be huge,…

Will New Marketing Push Pump Amarin Stock?
247sarah |

Will New Marketing Push Pump Amarin Stock?

Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the…

Gemphire Therapeutics Gears Up for IPO
Chris Lange |

Gemphire Therapeutics Gears Up for IPO

Gemphire Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Lee Jackson |

Why These 2 Biotech Stocks May Be Bought Out Soon

In a new report, Stifel sees two biotech stocks with near-term catalysts that could make takeover candidates soon.

Top Gaining Stocks

Builders FirstSource
BLDR • Vol: 2,729,564
IQVIA
IQV • Vol: 1,275,834
Mohawk Industries
MHK • Vol: 925,741
Charles River Laboratories
CRL • Vol: 650,123
PulteGroup
PHM • Vol: 2,478,220

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
Blackstone
BX • Vol: 5,773,852
Apollo Global Management
APO • Vol: 5,115,503
Seagate Technology
STX • Vol: 3,148,337
Skyworks Solutions
SWKS • Vol: 4,633,169